{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:31:20Z","timestamp":1783240280902,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12325-022-02179-1","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T18:03:47Z","timestamp":1653501827000},"page":"3308-3315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Antimo","family":"Moretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gimigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Iolascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"issue":"1","key":"2179_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79. https:\/\/doi.org\/10.1186\/s13023-017-0631-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2179_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2179_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fendo.2019.00794","volume":"22","author":"G Iolascon","year":"2019","unstructured":"Iolascon G, Paoletta M, Liguori S, Curci C, Moretti A. Neuromuscular diseases and bone. Front Endocrinol (Lausanne). 2019;22(10):794. https:\/\/doi.org\/10.3389\/fendo.2019.00794.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2179_CR4","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1007\/s00018-021-03821-x","volume":"78","author":"A Starosta","year":"2021","unstructured":"Starosta A, Konieczny P. Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. Cell Mol Life Sci. 2021;78(11):4867\u201391. https:\/\/doi.org\/10.1007\/s00018-021-03821-x.","journal-title":"Cell Mol Life Sci"},{"key":"2179_CR5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2353\/ajpath.2009.090052","volume":"175","author":"JV Welser","year":"2009","unstructured":"Welser JV, Rooney JE, Cohen NC, et al. Myotendinous junction defects and reduced force transmission in mice that lack alpha7 integrin and utrophin. Am J Pathol. 2009;175:1545\u201354. https:\/\/doi.org\/10.2353\/ajpath.2009.090052.","journal-title":"Am J Pathol"},{"issue":"3","key":"2179_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3.","journal-title":"Lancet Neurol"},{"issue":"8","key":"2179_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/1060028019900500","volume":"54","author":"M Bylo","year":"2020","unstructured":"Bylo M, Farewell R, Coppenrath VA, Yogaratnam D. A review of deflazacort for patients with Duchenne muscular dystrophy. Ann Pharmacother. 2020;54(8):788\u201394. https:\/\/doi.org\/10.1177\/1060028019900500.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"2179_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.nmd.2012.06.354","volume":"22","author":"AL Mayo","year":"2012","unstructured":"Mayo AL, Craven BC, McAdam LC, Biggar WD. Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord. 2012;22(12):1040\u20135. https:\/\/doi.org\/10.1016\/j.nmd.2012.06.354.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"2179_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","volume":"76","author":"S Joseph","year":"2019","unstructured":"Joseph S, Wang C, Bushby K, et al. Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar Database. JAMA Neurol. 2019;76(6):701\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0242.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2179_CR10","doi-asserted-by":"publisher","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah JK, Clemens PR, Guglieri M, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open. 2022;5(1):e2144178. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44178.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2179_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00198-010-1275-5","volume":"22","author":"ML Bianchi","year":"2011","unstructured":"Bianchi ML, Morandi L, Andreucci E, Vai S, Frasunkiewicz J, Cottafava R. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporos Int. 2011;22(2):529\u201339. https:\/\/doi.org\/10.1007\/s00198-010-1275-5.","journal-title":"Osteoporos Int"},{"key":"2179_CR12","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","volume":"23","author":"AM Sbrocchi","year":"2012","unstructured":"Sbrocchi AM, Rauch F, Jacob P, et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int. 2012;23:2703\u201311. https:\/\/doi.org\/10.1007\/s00198-012-1911-3.","journal-title":"Osteoporos Int"},{"issue":"3","key":"2179_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1359\/JBMR.051207","volume":"21","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res. 2006;21(3):374\u20139. https:\/\/doi.org\/10.1359\/JBMR.051207.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2179_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","volume":"158","author":"GL Forni","year":"2012","unstructured":"Forni GL, Perrotta S, Giusti A, et al. Neridronate improves bone mineral density and reduces back pain in \u03b2-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol. 2012;158(2):274\u201382. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09152.x.","journal-title":"Br J Haematol"},{"issue":"11","key":"2179_CR15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1080\/14656566.2019.1612367","volume":"20","author":"G Iolascon","year":"2019","unstructured":"Iolascon G, Moretti A. Pharmacotherapeutic options for complex regional pain syndrome. Expert Opin Pharmacother. 2019;20(11):1377\u201386. https:\/\/doi.org\/10.1080\/14656566.2019.1612367.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2179_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","volume":"68","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami S, Bertoldo F, et al. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo. 2016;68(1):1\u201339. https:\/\/doi.org\/10.4081\/reumatismo.2016.870.","journal-title":"Reumatismo"},{"issue":"1","key":"2179_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18(1):126\u201330. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.126.","journal-title":"J Bone Miner Res"},{"key":"2179_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/TCRM.S35788","volume":"9","author":"D Gatti","year":"2013","unstructured":"Gatti D, Rossini M, Viapiana O, Idolazzi L, Adami S. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013;9:139\u201347. https:\/\/doi.org\/10.2147\/TCRM.S35788.","journal-title":"Ther Clin Risk Manag"},{"key":"2179_CR19","volume-title":"Institute of Medicine. Dietary reference intakes for calcium and vitamin D","year":"2011","unstructured":"Ross AC, Taylor CL, Yaktine AL, Valle HBD, editors. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011."},{"issue":"6","key":"2179_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/BPO.0000000000000348","volume":"35","author":"KA James","year":"2015","unstructured":"James KA, Cunniff C, Apkon SD, et al. Risk factors for first fractures among males with Duchenne or Becker muscular dystrophy. J Pediatr Orthop. 2015;35(6):640\u20134. https:\/\/doi.org\/10.1097\/BPO.0000000000000348.","journal-title":"J Pediatr Orthop"},{"issue":"Suppl 2","key":"2179_CR21","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1542\/peds.2018-0333E","volume":"142","author":"LM Ward","year":"2018","unstructured":"Ward LM, Hadjiyannakis S, McMillan HJ, Noritz G, Weber DR. Bone health and osteoporosis management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Suppl 2):S34\u201342. https:\/\/doi.org\/10.1542\/peds.2018-0333E.","journal-title":"Pediatrics"},{"issue":"13","key":"2179_CR22","doi-asserted-by":"publisher","first-page":"117955142097240","DOI":"10.1177\/1179551420972400","volume":"6","author":"R Ronsley","year":"2020","unstructured":"Ronsley R, Islam N, Kang M, et al. Effects of bisphosphonate therapy on bone mineral density in boys with Duchenne muscular dystrophy. Clin Med Insights Endocrinol Diabetes. 2020;6(13):1179551420972400. https:\/\/doi.org\/10.1177\/1179551420972400.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"8","key":"2179_CR23","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1210\/clinem\/dgab302","volume":"106","author":"M Zacharin","year":"2021","unstructured":"Zacharin M, Lim A, Gryllakis J, et al. Randomized controlled trial evaluating the use of zoledronic acid in Duchenne muscular dystrophy. J Clin Endocrinol Metab. 2021;106(8):2328\u201342. https:\/\/doi.org\/10.1210\/clinem\/dgab302.","journal-title":"J Clin Endocrinol Metab"},{"key":"2179_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-012-0070-7","volume":"7","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2012;7:25\u201330.","journal-title":"Arch Osteoporos"},{"issue":"Suppl 1","key":"2179_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10195-017-0474-7","volume":"18","author":"U Tarantino","year":"2017","unstructured":"Tarantino U, Iolascon G, Cianferotti L, et al. Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. J Orthop Traumatol. 2017;18(Suppl 1):3\u201336. https:\/\/doi.org\/10.1007\/s10195-017-0474-7.","journal-title":"J Orthop Traumatol"},{"issue":"7","key":"2179_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nmd.2020.06.005","volume":"30","author":"C Tian","year":"2020","unstructured":"Tian C, Wong BL, Hornung L, et al. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. Neuromuscul Disord. 2020;30(7):599\u2013610. https:\/\/doi.org\/10.1016\/j.nmd.2020.06.005.","journal-title":"Neuromuscul Disord"},{"key":"2179_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/1179559X17732971","author":"A Corrado","year":"2017","unstructured":"Corrado A, Colia R, Cantatore FP. Neridronate: from experimental data to clinical use. Clin Med Insights Theraps. 2017. https:\/\/doi.org\/10.1177\/1179559X17732971.","journal-title":"Clin Med Insights Theraps"},{"key":"2179_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bone.2017.07.004","volume":"103","author":"L Idolazzi","year":"2017","unstructured":"Idolazzi L, Fassio A, Viapiana O, et al. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: data from open-label, not controlled, three-year Italian study. Bone. 2017;103:144\u20139. https:\/\/doi.org\/10.1016\/j.bone.2017.07.004.","journal-title":"Bone"},{"issue":"4","key":"2179_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00774-011-0331-3","volume":"30","author":"E Maines","year":"2012","unstructured":"Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F. Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab. 2012;30(4):434\u20138. https:\/\/doi.org\/10.1007\/s00774-011-0331-3.","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2179_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005;20(5):758\u201363. https:\/\/doi.org\/10.1359\/JBMR.041232.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2179_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mus.27416","volume":"64","author":"N Nasomyont","year":"2021","unstructured":"Nasomyont N, Tian C, Hornung L, et al. The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis. Muscle Nerve. 2021;64(6):710\u20136. https:\/\/doi.org\/10.1002\/mus.27416.","journal-title":"Muscle Nerve"},{"issue":"9","key":"2179_CR32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0883073816650034","volume":"31","author":"N Perera","year":"2016","unstructured":"Perera N, Sampaio H, Woodhead H, Farrar M. Fracture in Duchenne muscular dystrophy: natural history and vitamin D deficiency. J Child Neurol. 2016;31(9):1181\u20137. https:\/\/doi.org\/10.1177\/0883073816650034.","journal-title":"J Child Neurol"},{"issue":"6","key":"2179_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/BPO.0000000000000817","volume":"38","author":"A Singh","year":"2018","unstructured":"Singh A, Schaeffer EK, Reilly CW. Vertebral fractures in Duchenne muscular dystrophy patients managed with deflazacort. J Pediatr Orthop. 2018;38(6):320\u20134. https:\/\/doi.org\/10.1097\/BPO.0000000000000817.","journal-title":"J Pediatr Orthop"},{"key":"2179_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/928385","author":"JL Buckner","year":"2015","unstructured":"Buckner JL, Bowden SA, Mahan JD. Optimizing bone health in Duchenne muscular dystrophy. Int J Endocrinol. 2015. https:\/\/doi.org\/10.1155\/2015\/928385.","journal-title":"Int J Endocrinol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02179-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02179-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02179-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:08:21Z","timestamp":1662948501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02179-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2179"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02179-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}